Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 14/20 | 0.34 |
| ▸ | QPCT | Q16769 | 13/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7664653 | 0.91 | PDE4B (0.38) | GSK3BQPCT | |
| SCHEMBL7657220 | 0.91 | CAMK2D (0.42) | CAMK2DGSK3B | |
| SCHEMBL7658038 | 0.88 | GSK3B (0.33) | GSK3BQPCT | |
| SCHEMBL7655905 | 0.86 | EGLN1 (0.39) | CAMK2D | |
| SCHEMBL7660686 | 0.86 | CAMK2D (0.33) | CAMK2DGSK3B | |
| SCHEMBL7663240 | 0.85 | CAMK2D (0.38) | CAMK2DGSK3BQPCTDYRK1AMEN1 | |
| SCHEMBL7654047 | 0.84 | ASH1L (0.35) | CAMK2DGSK3BQPCTMAPT | |
| SCHEMBL7661970 | 0.84 | CAMK2D (0.32) | CAMK2DGSK3BMEN1KMT2A | |
| SCHEMBL7662871 | 0.83 | CAMK2D (0.40) | CAMK2DGSK3BQPCTDYRK1AMEN1 | |
| SCHEMBL7654136 | 0.82 | EGLN1 (0.39) | CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | claimed |
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |